Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow these two semaglutide products differ — and which one applies to weight management
What the evidence actually shows: oral semaglutide for weight loss
The clinical case for the Wegovy tablet rests on the OASIS 4 phase 3 trial, which enrolled 307 adults living with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. On average, participants taking the 25mg oral semaglutide lost around 13.6% of their body weight compared with around 2.4% on placebo, alongside lifestyle changes. Among those who stayed fully adherent to treatment, average weight loss reached roughly 16.6%. Those figures come from Novo Nordisk's UK approval announcement and the MHRA's review of the data, not from a single headline.
Ozempic's trial programme is built around glycaemic control in type 2 diabetes, not weight management. The SUSTAIN trials showed meaningful weight reduction as a secondary finding, which is why Ozempic developed a reputation in the weight-loss conversation, but a secondary finding in a diabetes trial is not a weight-loss licence. The licensed options for weight management in the UK are Wegovy (injection and tablet) and Mounjaro.
The MHRA's public guidance on GLP-1 medicines is clear that these treatments are not assessed or approved for quick or cosmetic weight loss, and the regulator has specifically flagged the risks of people obtaining semaglutide products outside their licensed indication. That guidance applies equally to Ozempic when used off-label.
The licences: what each product is actually approved for
A question our prescribers hear most weeks is some version of: "Can I just take Ozempic instead?" The short answer is that Ozempic's UK licence covers type 2 diabetes management, which means a prescriber can only lawfully issue it for that purpose through the normal clinical pathway. It is not something a weight-loss pharmacy can prescribe for weight management.
The Wegovy tablet, by contrast, holds a specific MHRA weight-management licence for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or prediabetes. Its dosing ladder runs from 1.5mg daily up to the 25mg maintenance dose, titrated over several months by the prescriber. That titration schedule exists to reduce the gastrointestinal side effects that are common at the start of treatment, nausea, diarrhoea and stomach discomfort are most noticeable early on and tend to settle as the body adjusts.
Rybelsus, the other oral semaglutide tablet, causes similar confusion. It uses the same molecule at 3mg, 7mg and 14mg doses and is licensed for type 2 diabetes. Those doses are not the same as the Wegovy tablet schedule and should not be treated as interchangeable steps. If you want to read more about that distinction, the Rybelsus vs semaglutide page covers it directly, and our comparison of oral semaglutide with traditional diabetes medicines gives further context on where these products sit clinically.
Side-by-side: Wegovy tablet vs Ozempic
| Wegovy tablet (oral semaglutide) | Ozempic (semaglutide injection) | |
|---|---|---|
| Active ingredient | Semaglutide + SNAC absorption enhancer | Semaglutide |
| UK licence | Weight management (adults, BMI ≥30 or ≥27 with comorbidity) | Type 2 diabetes only, not licensed for weight loss [Source: MHRA] |
| Route | Once-daily oral tablet | Once-weekly subcutaneous injection |
| Maintenance dose | 25mg daily | 1mg or 2mg weekly (diabetes dosing) |
| Average weight loss (trial) | ~13.6% over 64 weeks (OASIS 4, all participants) [Source: MHRA approval announcement, 11 Jun 2026] | Not trialled for weight loss at this dose; Wegovy injection at 2.4mg showed ~15% over 68 weeks (STEP 1) [Source: NEJM STEP 1] |
| Available from nume for weight loss? | Yes, subject to clinical assessment | No, not prescribed by nume for weight management |
The NHS page on semaglutide covers both products' approved uses and the safety profile in plain terms, and is a reliable first reference point.
What this means if you're weighing up oral treatment options
If you've been reading about Ozempic online and wondering whether it fits your situation, the honest answer is that it doesn't have a weight-loss licence in the UK, and obtaining it for that purpose would mean using a medicine outside the indication it was approved for. That matters because the dosing, the monitoring, and the clinical follow-up are all calibrated around its diabetes use.
The Wegovy tablet fills the gap that many people were looking for: a once-daily pill with no injections, no refrigeration, and MHRA-approved weight-management data behind it. It's still a prescription-only medicine, which means the route to it runs through a clinical assessment, not a checkout. Our clinical team reviews every consultation personally (a real prescriber reads your answers, not software) and if the Wegovy tablet is clinically suitable for you, a prescription can be issued the same day.
There's also the question of whether oral semaglutide or the Wegovy injection is the better fit for your circumstances, and separately whether tirzepatide (Mounjaro) might be worth considering. Those comparisons involve evidence from different trial populations and different mechanisms. They're worth thinking through rather than guessing at, and they're exactly what a consultation is designed to resolve. For anyone considering making the move from an injection to the tablet, our guide on switching covers what that process involves, and our Wegovy tablet prescription page explains what to expect step by step.
Which treatment suits you is a clinical decision our prescribers make with you, based on your health history, your preferences, and the evidence available.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.